

ASX release: 15th August 2017

Published study confirms the ePAT App is a valid and reliable point-of-care pain assessment app for people with dementia

- Peer reviewed article reporting the clinical validity of the ePAT App published in the Journal of Alzheimer's Disease
- Article indicates ePAT App offers significant advantage over current pain assessment methods
- ePAT is now working with the healthcare professional community to commercialise the ePAT App

A research article titled "Pain Assessment in Dementia: Evaluation of a Point-of-Care Technological Solution" has now been published in the prestigious peer reviewed Journal of Alzheimer's Disease. The published article indicates that the ePAT App is a valid and reliable pain assessment tool for people with moderate to severe dementia, who can no longer self-report their pain.

"We believe this is the first time a pain assessment tool using automated facial recognition technology and a smart device to assess people with dementia has been clinically validated in the residential aged care setting" said Mustafa Atee, one of the authors and ePAT's Scientific Officer.

The study also reports the ePAT App offers a significant advantage over current pain assessment methods, as the automated facial expression assessment feature provides an objective and reproducible evidence of the presence of pain.

"We announced the acceptance of this publication in July 2017 and are pleased to share the final published article with our shareholders and healthcare professionals. Moreover, in the past month the ePAT App has achieved the following two world first's; this peer reviewed publication and international regulatory clearance. These key milestones provide a foundation for the successful commercialisation of the ePAT App". said ePAT's CEO Philip Daffas.

ePAT is now working with healthcare professional partners to bring this essential technology to market. "Our goal is to provide the ePAT App as a global cost effective solution for carers of people who cannot verbalise their pain, initially commencing in Australia during Q4 2017 and Europe in 2018" added Daffas.

You can read the full journal publication through the link below:


<http://www.epattechnologies.com/news/pain-assessment-dementia-evaluation-point-care-technological-solution/>

Reference: Atee M, Hoti K, Parsons R, Hughes JD (2017) Pain assessment in dementia: Evaluation of a point-of-care technological solution. *J Alzheimers Dis* **60**, 1 [in Press].


About ePAT:

ePAT Technologies Limited is an Australian based company that has developed mobile medical applications to provide pain assessment for individuals that are unable to communicate verbally with their carers.

ePAT's technology, a mobile application, the ePAT App*, uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



ePAT artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



The ePAT App six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured through the ePAT App to calculate a pain severity score. Due to its ease of use and its reproducibility, the ePAT App will be able to be used in the first instance to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

The ePAT App will be rolled out globally in two phases: first, the ePAT App for Dementia for people who are unable to communicate effectively, and second, the ePAT App for Children who have not yet learnt to speak.

*The ePAT App is a Class 1 Medical Device that has TGA (Australia) and CE mark (Europe Economic Area) regulatory clearance.

For further information contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235